Last reviewed · How we verify
Motilium — Competitive Intelligence Brief
discontinued
Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Motilium (Motilium) — Rabin Medical Center.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Motilium TARGET | Motilium | Rabin Medical Center | discontinued | Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2 | ||
| Motilium | domperidone | Johnson & Johnson (Janssen) | marketed | Prokinetic agent / Antiemetic | Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2 | 1978-01-01 |
| Domperidon | Domperidon | Gadjah Mada University | marketed | Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Motilium — Competitive Intelligence Brief. https://druglandscape.com/ci/motilium. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab